An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases

Jad S. Husseini, Barbara Juarez Amorim, Angel Torrado-Carvajal, Vinay Prabhu, David Groshar, Lale Umutlu, Ken Herrmann, Lina Garcia Canamaque, Jose Ramon Garcia Garzon, William E. Palmer, Pedram Heidari, Tiffany Ting-Fang Shih, Jacob Sosna, Cristina Matushita, Juliano Cerci, Marcelo Queiroz, Valdair Francisco Muglia, Marcello H. Nogueira-Barbosa, Ronald J. H. Borra, Thomas C. KweeAndor W. J. M. Glaudemans, Laura Evangelista, Marco Salvatore, Alberto Cuocolo, Andrea Soricelli, Christian Herold, Andrea Laghi, Marius Mayerhoefer, Umar Mahmood, Ciprian Catana, Heike E. Daldrup-Link, Bruce Rosen, Onofrio A. Catalano*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Downloads (Pure)

Abstract

Background MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. Methods We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. Results Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. Conclusion PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.

Original languageEnglish
Number of pages16
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Early online date22-Feb-2021
DOIs
Publication statusPublished - 22-Feb-2021

Keywords

  • Skeletal
  • Osseous
  • Metastases
  • PET
  • MR
  • MRI

Cite this